SUMMARY In a double-blind randomised placebo-controlled trial of topical acyclovir in initial (first episode) genital herpes 18 patients received acyclovir ointment and 22 matching placebo ointment. Acyclovir significantly reduced the duration of viral shedding from external and all genital lesions, the duration of vesicles, the time to crusting, the time to complete healing of external and all genital lesions, new lesion formation, and the duration of pain, itching, and all symptoms combined for all patients. In female patients alone the time to crusting was not significantly different and the duration of pain only approached significance but the effects were otherwise the same as for all patients. No patients reported any adverse effects of treatment. Topical acyclovir is well tolerated and effective in treating initial genital herpes.
Introduction
Genital infection with herpes simplex virus is increasing in incidence. ' The primary or initial attack may be a severe illness with multiple genital and anorectal lesions appearing in crops from two to four weeks and occasionally with urinary retention and constipation due to pain and neurological involvement, root pains, and more distant disease such as adenitis and hepatitis. Such severe cases warrant admission to hospital and may benefit from intravenous treatment.2 Many initial attacks are milder and do not merit admission to hospital though the patient would benefit from treatment to shorten the symptomatic illness and the period of viral shedding.
Many remedies have been tried for the treatment of herpes simplex infection and their number reflects their doubtful efficacy. Acyclovir (Zovirax, Wellcome), an acyclic nucleoside guanosine derivative, has low toxicity and high antiviral activity in 
Results
Forty patients took part in the trial: eighteen were treated with acyclovir (group A) and 22 with the placebo (group B); 19 attended the Central Middlesex Hospital (centre 1) and 21 St Bartholomew's Hospital (centre 2). The sex ratios and age ranges of patients treated with acyclovir or placebo were similar (table I). The lesions were of similar severity in the two groups. The duration of lesions before presentation and the number of patients with other infections, complaining of pain, and with vesicles alone were similar in the two treatment groups; there were more patients with ulcers alone in the group treated with acyclovir (10 compared with seven) and all six patients with crusts already present were in the placebo group (table I) .
Thirty-four patients had virus recovered from cultures performed at entry, 14 in group A and 20 in group B (table I). All those with negative culture results had typical-looking lesions. At centre 2, 84%o of patients had herpes simplex virus type 2 and 16% had type 1. Fifteen of these isolates were tested for sensitivity to acyclovir and the median infective dose fig 1) . Differences were more pronounced for external lesions and less notable when all (external and internal) lesions were considered in women.
Healing-This was appreciably faster in patients in group A than in those in group B (table III and fig 2) . The median value for healing of all lesions in all patients in group A was nine days compared with 13 -5 days for those in group B. Furthermore, there was little new lesion formation among the actively treated patients (6%o) compared with those given placebo (45%). when all symptoms combined are considered their duration was also shorter with a median of five days in patients in group A compared with 10 days in the remainder (fig 3) . 16 1' 2'
Observer interaction-As two centres participated in the trial interaction between them was examined. Of all the indices assessed in tables 1I-IV a significant nal genital difference was noted only for "time to complete healing" for all patients and "duration of vesicles" for women.
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